Tag Archives: healthcare

Het Gastenhuis opens new care home for people with dementia

NPM part of SHV

Het Gastenhuis opens new care home for people with dementia

NPM portfolio company Het Gastenhuis has opened a new residential care home in Meppel for people with dementia. With this new location, the organisation aims to provide residents with a familiar and personal living environment. The opening was attended by local alderman Klaas de Vries, founder and CEO Annemieke Bambach, and location managers Karola and Jorinde.

 

According to the initiators, the opening is not just about a new building, but about creating a home. “Opening a home is different from opening a building,” said the location managers. “A building consists of bricks, walls and furniture, but a home is created by the people who live, work and visit there. Through attention, warmth and small moments that give life meaning.”

 

The Meppel location focuses on residential care, allowing people with dementia to continue their daily lives as much as possible in a way that suits them. “With this location, we aim to offer exactly that. A place where people feel seen, where there is space for who someone is and everything that comes with that. Where residents can continue to live their lives in a way that suits them, with as much independence and trust as possible.”

 

The Meppel home is the 34th Het Gastenhuis location in the Netherlands. Earlier this year, a new location opened in Huizen, with additional openings planned this month in Elst and later this year in Eindhoven.

Categories: News

Tags:

Carlyle Acquires Knack RCM and EqualizeRCM to Create an AI-Native, Global Multi-Specialty Healthcare RCM Platform

Carlyle

WOODBRIDGE, N.J., AUSTIN, Texas, and MUMBAI, India – May 4, 2026 – Global investment firm Carlyle (NASDAQ: CG) today announced it has acquired a majority stake in Knack RCM (“Knack”) and EqualizeRCM (“Equalize”), two leading U.S. healthcare revenue cycle management (“RCM”) providers, to create an AI-native, global, multi-specialty RCM platform. Equity for the investment will come from investment funds affiliated with Carlyle Asia Partners VI (CAP VI) and Carlyle Asia Partners Growth II (CAPG II). The terms of the transaction are not disclosed. Rajiv Sharma, Founder of Knack RCM, and Nagi Rao, Founder of EqualizeRCM, will remain invested in the platform through a reinvestment of a portion of their proceeds.

 

Knack and Equalize are complementary healthcare RCM providers serving physician groups, durable medical equipment (“DME”) providers, rural hospitals, and other specialty provider segments. Together, they bring deep, specialty-specific expertise across DME, anaesthesia, eyecare, behavioural health, rural hospitals, urgent care, and multi-specialty physician groups.

 

The combined platform is expected to enhance operational scale and diversification, broaden the delivery footprint, strengthen leadership depth and help accelerate AI capabilities to enhance outcomes for clients. Knack contributes scaled, global delivery across the U.S., India, and the Philippines, anchored by an intelligent, end-to-end revenue engine powered by its orchestration platform, Workmate. EqualizeRCM complements this with its established delivery scale in the U.S. and India, alongside a proprietary payer enrollment platform and advanced AI-driven tools—such as Bill Smart for denial prediction and avoidance— that are purpose-built for hospitals, urgent care, and targeted specialty segments. Equalize’s AI-native platform, built on large language models and agentic AI, has demonstrated proven commercial traction, including the displacement of established, large-scale vendor contracts at leading DME manufacturers.

 

Kapil Modi, Partner at Carlyle India Advisors, said: “The U.S. healthcare revenue cycle market is growing rapidly, driven by margin compression, workforce shortages, and the shift to value-based care. Carlyle has significant experience in scaling RCM platforms to achieve market leadership and we believe Knack and Equalize stand out as leaders with their AI-native, specialty‑focused, and outcomes‑driven approach, which aligns well with the growing needs and demand in healthcare RCM.”

 

Rajiv Sharma, Founder, Knack RCM, said: “Carlyle has been a trusted partner to Knack, bringing not only capital but also valuable expertise in healthcare and RCM. The addition of Equalize is a progression of this partnership and strengthens the value we provide to our clients.”

 

Nagi Rao, Founder, EqualizeRCM, said: “Our clients, particularly rural hospitals and behavioural health providers, face immense pressure in sustaining margins and ensuring access to care. Partnering with Knack enables us to integrate our advisory expertise with their advanced analytics and global operations, to deliver more robust and tailored solutions. We are excited to work with Knack and Carlyle to drive wider adoption of our AI-native platform to support healthcare providers.”

 

Gautam Barai, CEO, Knack RCM, said: “Healthcare providers measure success by their ability to meet payroll, preserve services, and support their communities—not by the amount of automation deployed. Coming together with Equalize allows us to combine our strengths to tackle the most complex parts of the revenue cycle, including rural cost reports, DME intake, and challenging anaesthesia cases. For us, success is not about automating simple workflows but about addressing the most critical financial risks faced by our clients, which ultimately translates into improved financial health and better patient care.”

 

Amit Jain, Partner and Head of Carlyle India Advisors, concluded: “One of the core tenets of this investment is to build a scaled, strategically attractive physician and rural hospital RCM platform in a fragmented industry. Carlyle has a track record of executing similar strategies in sectors such as auto components and pharmaceuticals. This investment extends our India for the World thesis and builds on our experience investing in technology and tech-enabled services. We have invested in healthcare technology platforms including Indegene, Visionary RCM, and CorroHealth, and we will bring this expertise and execution capability to scale the combined Knack and Equalize platform.”

 

Carlyle intends to build on this platform strategy by pursuing additional opportunities in the RCM industry and will continue to seek to add synergistic assets with complementary offerings to the RCM platform.

 

***

 

About Carlyle

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Carlyle AlpInvest. With $477 billion of assets under management as of December 31, 2025, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,500 people in 27 offices across four continents. Further information is available at carlyle.com. Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group.

 

About Knack RCM
Knack RCM is an AI-native, specialty‑focused revenue cycle management leader that helps healthcare organizations operating in complex clinical, financial and technology environments unlock the full value of reimbursement, safeguard margin and strengthen the delivery of care, so providers can better serve the communities that depend on them. Headquartered in Woodbridge, New Jersey, Knack RCM has over 8,000 employees across 10 delivery centers in India, the Philippines and the United States.

 

About EqualizeRCM
EqualizeRCM is a U.S.‑based revenue cycle management company serving physicians, hospitals, ambulatory surgery centers, laboratories and rural providers. The company is known for its work with Critical Access Hospitals, rural PPS Hospitals and Rural Health Clinics, providing specialized support in cost reports, reimbursement strategies and education forums that help clients navigate evolving payer and regulatory environments. The Company’s 1st Credentialing division is a leading provider of payor enrollment services across the nation.

 

 

Media Contacts

 

Carlyle
Lonna Leong
+852 9023 1157
lonna.leong@carlyle.com

Categories: News

Tags:

ARCHIMED Diagnostics, along with minority investor La Caisse, acquires Stago, a global leader in blood coagulation analysis

LaCaisse
  • Working with Stago management, ARCHIMED aims to expand sales and profits by building on gold-standard products in both developed and developing nations

ARCHIMED Diagnostics – the Diagnostics team of global private equity healthcare specialist ARCHIMED – has purchased alongside global investment group La Caisse (formerly CDPQ), Stago, a world leader for the analysis of blood coagulation issues (hemostasis). Stago develops and manufactures hemostasis equipment and reagents. It has unique expertise and a track record of innovation in this specialty.

Stago is held through ARCHIMED’s MED Platform II fund and was purchased from the founding Viret family by the Diagnostics team through an unspecified mix of equity and unitranche debt. Stago sells its products in 115 countries and posted revenues of €550 million in 2025. Based in Asnières-sur-Seine (greater Paris), Stago was founded in 1945 and is the only pure-play hemostasis analysis company in the world. Stago’s leadership team is taking a minority stake as part of the deal.

“In addition to financial muscle, ARCHIMED and La Caisse have the operational sophistication and discretion to help us grow at a pivotal moment in our company’s history,” says incumbent Stago CEO Jean‑Claude Piel, who retires from his post, becoming Chief of the Scientific and Technology Monitoring Committee. “ARCHIMED’s diagnostics expertise is key for accelerating the efficient rollout of a major, new generation of Stago products,” says Philippe Barroux, Stago’s CEO-elect. Barroux, a 38‑year Stago veteran, is currently CEO of operations in North America and China. “This partnership is all about reigniting innovation at Stago.”

ARCHIMED has made a total of eight diagnostics acquisitions, exiting two: Diesse, which became a pioneer in the development of cutting-edge systems for diagnosing inflammatory diseases and immune disorders in partnership with ARCHIMED; and Eurolyser, a point-of-care testing specialist, which saw profits rise more than two-fold and sales growth accelerate from the high single-digits to 25 percent annually during three years of ARCHIMED ownership.

“Our aim is to provide Stago with the resources it needs to accelerate global growth and to reinforce its leading position as a pure player with unrivalled expertise,” says ARCHIMED Managing Partner Vincent Guillaumot. “Stago has a pipeline of innovative products that should allow its revenues and profits to grow well above industry averages,” adds ARCHIMED Partner Antoine Faguer.

“Stago is a recognized leader in blood coagulation analysis, operating in a segment we know well, and serving a mission-critical role in medical diagnostics. Our investment alongside ARCHIMED reflects the value we place on partnerships and businesses with strong fundamentals,” said Martin Longchamps, Executive Vice-President and Head of Private Equity and Private Credit at La Caisse.

Working closely with Stago management, ARCHIMED will deploy its MedValue template – ARCHIMED’s levers for accelerating the growth of partnering companies via internationalization (often including bolt-on acquisitions), innovation and product range expansion.

Diagnostics is a primary investment sector for ARCHIMED, and one of the seven major sectors mapped through ARCHIMED’s MedSeg, its proprietary sector analysis tool covering 430 sub-segments of the global health industry. For the acquisition of Stago, ARCHIMED also deployed MedDiscover, a proprietary set of tools and processes permitting ARCHIMED to identify and effectively engage with leading companies operating in ARCHIMED’s prioritized sub‑sectors.

Stago is MED Platform II’s 10th investment. All of MED Platform II’s investments have been first-time leveraged buyouts for the companies acquired. MED Platform II, more than two times oversubscribed, closed on €3.5 billion in June, 2023. According to Preqin data, the fund is a top quartile performer for its vintage year as are all ARCHIMED funds. After the Stago transaction, MED Platform II is some 70 percent invested.

ABOUT ARCHIMED

www.archimed.group – With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Services, and MedTech. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €9 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation.

ABOUT LA CAISSE

At La Caisse, formerly CDPQ, we have invested for 60 years with a dual mandate: generate optimal long-term returns for our 48 depositors, who represent over 6 million Quebecers, and contribute to Québec’s economic development.

As a global investment group, we’re active in the major financial markets, private equity, infrastructure, real estate and private credit. As at December 31, 2025, La Caisse’s net assets totalled CAD 517 billion. For more information, visit lacaisse.com or consult our LinkedIn or Instagram pages.

La Caisse is a registered trademark of Caisse de dépôt et placement du Québec that is protected in Canada and other jurisdictions and licensed for use by its subsidiaries.

– 30 –

For more information

Categories: News

Tags:

McKesson Signs Agreement with Apollo Funds for Strategic Minority Interest in Medical-Surgical Solutions

Apollo logo

IRVING, Texas, April 20, 2026 – McKesson Corporation (NYSE: MCK), a leading Healthcare Services company, today announced it has entered into a definitive agreement with funds managed by affiliates of Apollo (“Apollo Funds”), under which Apollo Funds will acquire a minority ownership interest in McKesson’s Medical-Surgical Solutions (“MMS”) business. This transaction represents a meaningful milestone as McKesson executes its separation strategy of MMS in preparation of a planned initial public offering.

Apollo Funds will invest $1.25 billion in convertible preferred equity of MMS to acquire an approximately 13% minority interest in MMS. The transaction values MMS at approximately $13 billion total enterprise valuation. McKesson will retain operating control and majority ownership of MMS and consolidate the results for financial reporting. The transaction is subject to regulatory approvals and customary closing conditions.

“This transaction marks a key milestone in McKesson’s planned separation of MMS,” said Brian Tyler, chief executive officer of McKesson. “We are pleased to welcome Apollo as an important strategic and financial partner. Apollo’s experience in supporting complex carve-out and public market transactions will be additive as we position MMS for success, while maintaining McKesson’s financial and strategic flexibility. We look forward to working together to execute the separation in a manner that maximizes shareholder value, and establishing a well-capitalized, world-class medical surgical supply and solutions company.”

“MMS is a leading healthcare platform with a talented team and strong market position, playing a key role in healthcare supply chain resiliency across non-acute care settings,” said Apollo Partner Maxwell David and Managing Director Jeff Armstrong. “We believe the business is well positioned for continued growth, and that Apollo’s Hybrid platform enables us to provide flexible, scaled capital to support the next phase of development as MMS prepares to operate as a standalone company.”

Cautionary Statements

Statements in this press release about of the anticipated completion of Apollo’s investment in MMS, McKesson’s intent to separate MMS into an independent company, the planned initial public offering (“IPO”) of MMS, and the expected benefits of the transactions described, including anticipated timing, plans, expectations, commitments and intentions, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Readers should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly update forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Although it is not possible to predict or identify all such risks and uncertainties, risk factors include, but are not limited to: Apollo’s investment and the planned separation and IPO of MMS are contingent upon the satisfaction of certain conditions, may not be completed on the currently contemplated terms or timeline, or at all, and, if completed, may not achieve the intended financial and strategic benefits; unanticipated business, market, governmental, or other developments could delay or prevent completion of Apollo’s investment, the separation, or the IPO, or cause any of the transactions to occur on less favorable terms; the transactions described are subject to conditions that may not be satisfied on the expected timeline, or at all, which could delay or prevent closing; we may be unsuccessful in achieving our strategic growth objectives; we might be adversely impacted by changes in the economic environments in which we operate; and we might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events, and other catastrophic events. We encourage investors to read the important risk factors described in McKesson’s most recent Form 10-K filed with the Securities and Exchange Commission.

About McKesson Corporation

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Stories & Insights.

About Apollo

Apollo is a high-growth, global alternative asset manager. Apollo’s asset management business  seeks to provide its clients excess return at every point along the risk-reward spectrum from investment grade credit to private equity. For more than three decades, Apollo’s investing expertise across its fully integrated platform has served the financial return needs of its clients and provided businesses with innovative capital solutions for growth. Athene, Apollo’s retirement services business, specializes in helping clients achieve financial security by providing a suite of retirement savings products and acting as a solutions provider to institutions. Apollo’s patient, creative, and knowledgeable approach to investing aligns its clients, the businesses it invests in, its employees, and the communities it impacts, to expand opportunity and achieve positive outcomes. As of December 31, 2025, Apollo had approximately $938 billion of assets under management. To learn more, please visit www.apollo.com

Contacts

McKesson Corporation

Investors
Investors@McKesson.com

Media Relations
MediaRelations@McKesson.com

Apollo

Noah Gunn
Global Head of Investor Relations
Apollo Global Management, Inc.
(212) 822-0540
IR@apollo.com

Joanna Rose
Global Head of Corporate Communications
Apollo Global Management, Inc.
(212) 822-0491
Communications@apollo.com

Categories: News

Tags:

Eurobio Scientific signs definitive agreement to acquire CareDx’s transplant lab production division

IK Partners

Acquisition of CareDx’s ‘lab products’ portfolio creates new opportunities for growth and innovation in the fast growing transplant diagnostics market 

  • Acceleration of Eurobio’s strategic plan to become an in-vitro molecular diagnostics (“IVD”) leader
  • Creation of a global leading provider of kits for transplantation genomics
  • Acquisition of a 100% proprietary products portfolio
  • Deeper capabilities and larger scale with technological and commercial complementarities

Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in-vitro medical diagnostics for transplantation, oncology and infectious diseases, today announces that it has entered into a definitive agreement to acquire the Lab Products division of CareDx, a US global precision medicine company focused on transplantation.

Through the acquisition of CareDx’s Lab Products division, the transaction brings together two highly complementary portfolios in human leukocyte antigen (“HLA”) typing and transplantation diagnostics. It combines Eurobio Scientific affiliate GenDx’s expertise in next-generation sequencing (“NGS”) assays, software and global commercial footprint, with CareDx’s portfolio of HLA-typing and transplant monitoring kits as well as its market leading customer service.

Strategic Rationale

This acquisition enables GenDx to offer a more comprehensive portfolio across the transplantation IVD workflow, from pre-transplant HLA typing to post-transplant monitoring solutions. The combined entity will offer an expanded portfolio of molecular assays, reagents, and software, with the aim of enabling laboratories to streamline operations and improve clinical outcomes.

The integration of CareDx’s LabProducts division strengthens GenDx’s presence in key markets, including the United States, Europe and Asia-Pacific, while enhancing its ability to serve both research and clinical laboratories.

Key Highlights

  • Expanded Product Portfolio: Integration of CareDx’s HLA typing kits, including real-time polymerase chain reaction (“PCR”) and NGS-based solutions, with GenDx’s NGS assays and software platforms
  • Global Commercial Scale: Enhanced distribution capabilities and customer access across major transplantation markets
  • Technology Synergies: Acceleration of innovation in high-resolution HLA typing, hybrid capture, and transplantation monitoring workflows
  • Operational Efficiencies: Opportunities to streamline manufacturing and supply chain operations

Leadership Commentary

“This acquisition marks a significant milestone in our mission to advance precision medicine in transplantation,” said Denis Fortier, CEO of Eurobio Scientific. “By combining our technological leadership with CareDx’s strong Lab Products portfolio, we are uniquely positioned to deliver comprehensive solutions to transplant laboratories worldwide.”

John Hanna, CEO of CareDx, added: “This transaction allows us to further focus on our core strengths in U.S.‑based Precision Medicine Diagnostic Testing Services and Patient and Digital Solutions, while ensuring that our Lab Products business continues to thrive under Eurobio’s leadership.”

Transaction Details

The transaction is subject to customary closing conditions and regulatory approvals. Under the terms of the agreement, Eurobio Scientific will acquire CareDx’s Lab Products business in cash for an equivalent of €145 million ($170 million), subject to customary adjustments.

Following closing, the LabProducts division will be integrated into GenDx’s operations, with a focus on maintaining continuity for customers, partners, and employees.

Eurobio Scientific is represented by TD Cowen and Kahn Partners in this transaction.  CareDx is represented by Rothschild & Co. and Fenwick.

Contacts

Groupe Eurobio Scientific
Denis Fortier, Chairman and CEO
Olivier Bosc, Deputy CEO/ CFO Tel. +33(0) 1 69 79 64 80

Actus
Mathieu Calleux
Investors Relations Tel. +33(1) 53 65 68 68 – eurobio-scientific@actus.fr

About Eurobio Scientific

Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, oncology, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 290 employees and four production units based in the Paris region, in Germany, in the Netherlands and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany, Antwerp Belgium, Utrecht in The Netherlands and Milan in Italy. Eurobio Scientific’s reference shareholder is the Eurobio Development Holding company which brings together its two directors, Jean-Michel Carle and Denis Fortier, alongside IK Partners, “Pépites et Territoires” by AXA & NextStage AM investment program managed by NextStage AM as well as Jérome de Castrie. For more information, please visit: www.eurobio-scientific.com The company is publicly listed on the Euronext Growth market in Paris Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label. Symbol: ALERS – ISIN Code: FR0013240934 – Reuters: ALERS.PA – Bloomberg: ALERS:FP

Read More 

Categories: News

Tags:

Bain Capital and Evergreen Medical Properties Acquire Portfolio of Six Medical Outpatient Facilities in Atlanta Metropolitan Area

BainCapital

ATLANTA and BOSTON – April 9, 2026 – Bain Capital’s Real Estate team (“Bain Capital”) and Evergreen Medical Properties (“Evergreen”) today announced the acquisition of a medical outpatient building portfolio consisting of six assets totaling approximately 665,000 square feet in the Atlanta metropolitan area.  The private, off-market purchase was completed via a partnership between Bain Capital and Evergreen that focuses on acquiring, renovating, and operating mission-critical medical outpatient buildings.

The Class-A medical outpatient buildings are anchored by Northside Hospital, a leading, award-winning healthcare provider operating five acute-care hospitals and nearly 500 outpatient facilities across 25 counties in the Atlanta MSA. Northside leads the U.S. in newborn deliveries and is among Georgia’s top providers of cancer care, sports medicine, cardiovascular and surgical services. The portfolio is 93% leased and features other dynamic tenants spanning diverse specialties and high-acuity services.  The assets are located in “Pill Hill” and Alpharetta, two high-demand, affluent Atlanta submarkets.

“We’re pleased to expand our presence in Atlanta, a high-conviction market, as well as our relationship with Northside Hospital as we execute a value creation plan alongside the Evergreen team that enhances the facilities’ ability to better serve patients across the Atlanta area,” said Lukas Gregg, a Managing Director at Bain Capital.  “This transaction is an attractive opportunity to acquire a high-quality portfolio of mission-critical assets supported by strong market dynamics and we are grateful to be the new stewards of it.”

“We’re ecstatic Northside chose to expand our relationship with some of the health system’s most strategically important medical outpatient buildings,” said Joshua Richmond, President of Evergreen Medical Properties. “We look forward to working closely with Northside as we build upon Evergreen’s strong track record of aligning capital and healthcare partners through the stewardship of mission-critical real estate.”

The acquisition of these buildings follows the partnership’s recent purchase of a two-asset portfolio in Lawrenceville, GA, also anchored by Northside Hospital.  Bain Capital and Evergreen have curated a portfolio of institutional quality medical outpatient buildings in select markets throughout the U.S. and are actively seeking to grow its 2M square foot footprint.

Northside was advised by Realty Trust Group, a national healthcare advisory firm.

###

About Bain Capital Real Estate
Bain Capital Real Estate pursues investments in often difficult-to-access sectors underpinned by enduring secular trends that drive long-term demand growth for real estate assets and services. The Bain Capital Real Estate team has invested and committed over $10.7 billion of equity across multiple sectors as of September 30, 2025. Bain Capital Real Estate focuses on assets where the team applies its deep industry expertise to accelerate impact and drive operational improvements. Bain Capital Real Estate’s strategy aligns with the value-added investment approach that Bain Capital pioneered and leverages the firm’s global platform and significant experience across asset classes to further bolster its insights and sourcing capabilities. Bain Capital is one of the world’s leading private investment firms, with approximately $219 billion of assets under management. For more information, visit https://www.baincapitalrealestate.com.

About Evergreen Medical Properties  
Evergreen Medical Properties, with offices in both Denver and Atlanta, is a full-service real estate operating company that invests, leases and manages healthcare facilities across the United States. Evergreen uses a collaborative approach to invest in strategic healthcare real estate in order to align interests and build genuine relationships with health systems and providers.  Evergreen seeks to unlock capital, enhance the operating flexibility of its partners and create durable, long-term value in each of its healthcare real estate investments.

About Northside Hospital
The Northside Hospital healthcare system is one of Georgia’s leading healthcare providers with five acute-care hospitals in Atlanta, Canton, Cumming, Duluth, and Lawrenceville and nearly 500 outpatient locations across the state. Northside Hospital leads the U.S. in newborn deliveries and is among the state’s top providers of cancer care, sports medicine, cardiovascular, and surgical services. For more information, visit: www.Northside.com.

Categories: News

Tags:

Verdane and Bpifrance partner with Medadom to expand access to healthcare services in France and across Europe

Verdane Capital

Verdane, the European specialist growth buyout investment firm, today announces an investment into and partnership with Medadom, a leading French teleconsultation provider, alongside Bpifrance, the French sovereign fund.

Verdane has extensive experience navigating regulated reimbursement environments and scaling technology-enabled healthcare platforms such as Pflegecampus, Evondos and Smartbox.

Founded in 2017, Medadom has played a pioneering role in shaping teleconsultation in France. The company was the first teleconsultation provider to receive accreditation from the French Ministry of Health and has established a leading position in the market through a high-quality, secure and accessible model of care.

In addition to its pure digital offering, Medadom operates 5,500 physical teleconsultation units in pharmacies and optical stores across France and has facilitated more than 9 million teleconsultations. The company provides an important digital healthcare solution in areas affected by limited access to medical professionals, helping to improve access to care for underserved populations.

The investment will support Medadom in expanding access to healthcare services in France and across Europe, broadening its service to include additional care verticals and further strengthening its medical governance and technology platform. Over time, the partnership is also intended to support a measured expansion into other European markets, building on the company’s established position in France.

As part of the transaction, Medadom founders Elie-Dan Mimouni and Nathaniel Bern regain majority ownership of the business as they partner with Verdane and Bpifrance to support the next stage of the company’s development. Medadom’s former partner Gsquare Capital has realised its investment in the business.

The investment in Medadom marks Verdane’s first investment in France, a natural step for the firm as it continues its European growth investment strategy.

Completion of the transaction is expected later in 2026, subject to customary regulatory approvals and closing conditions.

Elie-Dan Mimouni, Co-Founder of Medadom, said: “Verdane and Bpifrance’s investments mark a strategic milestone for Medadom. Their combined expertise in healthcare and technology will enable us to create even greater value for patients, our partner pharmacists and opticians, as well as for the physicians practicing on our platform, while further consolidating a demanding, responsible model centered on the quality of medical care delivery.”

Moez Gharbi, Partner at Verdane, said: “Our in-depth analysis of the healthcare technology sector made it clear that Medadom stands out as a trusted, scalable leader in telehealth. Its distinctive model combines medical excellence with accessible, technology-enabled care. We have been particularly impressed by the powerful flywheel inherent to its unique digital and phygital approach, the strength of its governance and its clear commitment to responsible healthcare delivery. At the same time, it is encouraging to see French authorities taking thoughtful steps to improve access to care, particularly in underserved areas. We look forward to working closely with Elie-Dan, Nathaniel and the wider Medadom team along with Bpifrance to invest in the company’s continued growth.”

Benoist de Saint Lager, Senior Investment Director at Bpifrance said: “Our investment in Medadom is fully aligned with our investment thesis: addressing the major societal challenge of providing healthcare access for everyone across the country. Teleconsultations have proven to be an effective way to tackle healthcare accessibility issues, ease pressure on the healthcare system by increasing available medical time and relieve congestion in hospital emergency departments. As Medadom’s partner, Bpifrance aims to support the long-term development of its teleconsultation offer in France, where there is still significant room for market penetration improvement when compared with some European neighbours that are currently more advanced in the telehealth field.”

About Medadom

Founded in 2017, Medadom is a French teleconsultation provider accredited by the French Ministry of Health. The company delivers secure and patient-centred remote medical consultations through a network of more than 5,500 teleconsultation kiosks located in pharmacies and optical stores across France. With more than 9 million consultations completed, Medadom plays a central role in improving access to healthcare, particularly in medically underserved areas. The company has been part of the French Tech 120 programme since 2021, a Government-led flagship initiative designed to support and accelerate the growth of France’s most promising scale-ups.

About Verdane

Verdane is a specialist growth buyout investment firm that partners with tech-enabled and sustainable businesses that help to digitalise and decarbonise the European economy. The flexible mandates of Verdane funds allow it to invest as a majority or minority control investor, replacement or growth capital, in single companies or in portfolios of companies

Verdane has raised €9 billion in capital and its funds have made more than 200 investments in fast-growing businesses since 2003. Verdane’s team of over 150 investment professionals and operating experts is based out of Berlin, Copenhagen, London, Helsinki, Munich, Oslo and Stockholm and combines deep sector expertise with long-standing local networks and presence in core European markets.

Verdane is also a certified B Corporation, the most ambitious sustainability accreditation globally. The firm only backs businesses that pass its 2040 test, which indicates whether the company can thrive in a more sustainable future economy.

Verdane is partly owned by the Verdane Foundation, which is focused on two areas: climate change and more equitable and inclusive local communities.

More info: www.verdane.com
Follow Verdane on LinkedIn

Press Contact

Verdane Press Office
press@verdane.com

About Bpifrance

Bpifrance Investissement is the management company that handles Bpifrance’s equity investments. Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export…). For more information, please visit: https://www.bpifrance.com/ Follow us on Twitter: @Bpifrance – @BpifrancePresse and LinkedIn.

Categories: News

Tags:

819 Capital Partners acquires key assets of Lead Pharma, enabling continuation of operations

819 Capital Partners

Deventer, 6 March 2026 – 819 Capital Partners has acquired the key assets of Lead Pharma, thereby realizing a continuation based on the company’s patent portfolio and associated research programs.

The transaction includes intellectual property rights, research data, and selected development programs.

Lead Pharma develops innovative small-molecule medicines for the treatment of cancer and autoimmune diseases. Over the past years, the company built a strong research platform and multiple drug candidates, collaborating with international pharmaceutical companies such as Roche and Sanofi.

The acquisition is realized by 819 Capital Partners, through its 819 Evergreen Fund, together with Waterman Ventures and the former management of Lead Pharma. Going forward, the focus will be on the further development and valorization of the most promising components of the portfolio of Lead Pharma.

Following a period of financial restructuring, the activities have been secured through an asset transaction. This transaction lays a new foundation for the continuation and further development of the programs, and for entering into new collaborations aimed at advancing development.

Frans van den Berg, Chief Executive Officer of Lead Pharma, commented: “This asset acquisition with the support of 819 Capital Partners enables us to continue Lead Pharma’s projects in a focused manner and to make the development of new medicines for patients possible.”

819 Capital Partners views the transaction as a strategic investment in a mature biotech patent portfolio, with the aim of advancing the development of the programs and creating value through further development and strategic partnerships.

About 819 Capital Partners

819 Capital Partners is an investment firm managing multiple funds with targeted investment strategies. Its open-ended 819 Evergreen Fund is quarterly open for new investors and invests in companies focused on deep-tech and med-tech. The firm invests in sectors such as healthcare and technology, addressing societal challenges including aging populations.

Categories: News

Tags:

Axon Diagnostics joins Medica Group to enhance UK diagnostic services

IK Partners

On 13 February Axon Diagnostics joined Medica Group, marking an exciting new chapter for our organisation and for the future of remote diagnostics in the UK.

By joining forces, we will become the UK’s largest clinical reporting network, supporting more than 2.5 million patients each year across the majority of NHS Trusts. This step reflects our shared ambition to accelerate innovation and gives us the scale, and capability, to support even more patients with faster, accurate reporting.

As part of this integration, Axon’s sister company, MITIS Health, will also join Medica. MITIS brings its Clinical Desktop technology, already trusted by many NHS Trusts, to support high fidelity remote diagnostic reporting.

Strengthening our capabilities together

For more than 20 years, we have built a robust network of specialist clinicians, supported by strong clinical governance and advanced infrastructure. By welcoming Axon and MITIS into the Medica Group, we are enhancing this foundation even further.

Axon is known for its innovative technology platform, agile workflows, and secure, high-performance remote desktop solutions powered by MITIS Clinical Desktop. These tools allow clinicians to work with complete flexibility, seamlessly and securely, from any appropriate location. Axon also brings a team of highly skilled clinicians who have earned a reputation for their quality and responsiveness.

Together, these strengths mean we can offer:

  • More capacity for clients across the UK
  • Faster turnaround times for routine and urgent cases
  • An enhanced experience for both healthcare partners and patients
  • A stronger platform for innovation, including AI-enabled reporting and optimised workflows

The UK’s largest clinical reporting network

With Axon joining Medica, we will be working with the majority of NHS Trusts and covering a broad range of diagnostic subspecialties.

Both organisations share the same commitment: to act as trusted strategic partners and deliver consistent, transparent, high-quality diagnostic services. Our clients will continue to work with the same familiar teams, while gradually benefiting from enhanced tools, streamlined workflows, and increased flexibility as our systems integrate.

Leadership insights

Andrew Cannon, Chief Executive Officer of Medica Group, said: “This merger marks a significant milestone for Medica, and we are proud to welcome Axon into the Medica Group. The Axon team has built an exceptional business in a remarkably short time, earning the trust of clients through first-rate service, agility and a deep commitment to quality. Bringing Axon into Medica strengthens our position as the UK’s leading diagnostics provider. Clients will continue to receive the excellent service they rely on, now supported by greater capacity and advanced reporting technology. We look forward to building a compelling future together, driving further innovation and delivering outstanding patient care at the core of our mission.”

Rahul Mehta, Chief Executive Officer of Axon Diagnostics, said: “Axon was founded to push the boundaries of diagnostic innovation, and joining Medica enables us to amplify that mission. This merger combines our technology and agile approach with Medica’s scale and clinical excellence, meaning more patients will benefit from faster and smarter reporting. We’re excited to enter this next chapter together, bringing our teams and clients with us into the Medica Group as we continue building trusted, high-quality diagnostic services.”

What happens next

We are now working through a phased integration plan that will bring together our systems, teams, and best practices in a structured and transparent way. While this integration progresses, our focus remains firmly on delivering reliable, high-quality diagnostic services that place patients at the centre of every decision we make. We look forward to the opportunities this partnership will unlock as we continue working together to deliver the highest standards of diagnostic care.

Contacts

Medica
Helen Lawton
Group Head of Marketing, Communications and Events
Email: Helen.lawton@medica.co.uk
Tel: 07950179069

FTI Consulting
Ben Atwell / Sam Purewal
Email : medica@fticonsulting.com
Tel: +44 (0) 203 727 1000

About Medica

Medica Group is the UK’s largest telemedicine diagnostics provider, delivering expert teleradiology and telepathology services to over half of NHS hospitals nationwide. With more than 20 years’ experience in remote diagnostics, Medica provides 24/7 coverage for urgent and routine imaging via a network of 800+ specialist clinicians across the UK, Ireland and the US. Its innovative platforms and use of AI-enhanced workflows help healthcare providers reduce imaging backlogs and improve patient outcomes. Headquartered in Hastings, UK, Medica Group also encompasses Medica Ireland (managed radiology and pathology services in Ireland) and RadMD in the USA (clinical trial imaging), underscoring its international reach and commitment to “improving lives through excellence in diagnostics and research.”

Read More 

About Axon Diagnostics

Axon Diagnostics is a UK-based, clinically led diagnostics services provider delivering radiology, teleradiology and digital pathology services to the NHS and private healthcare organisations. Axon offers a suite of solutions to support the needs of modern diagnostic imaging services, underpinned by innovative, secure streaming technology that enables efficient reporting, supports clinicians, and delivers tangible benefits for patient care. Axon Diagnostics – Radiology Reimagined.

Read More 

About MITIS Health

MITIS Health is a UK-based technology provider focused on improving diagnostic workflows. MITIS Health has built the Next Generation Home and inHospital Reporting Solution for Radiology, Pathology and Clinical Desktops. The Company’s Secure Gateway allows clinicians working remotely to securely project a desktop located in the hospital or datacentre, directly to any appropriate remote location. Complete lossless transmission / zero degradation of images is supported for all light-based scans such as: Plain Film, CT, MRI, PET, Ultrasound and Histopathology.

Read More 

Categories: News

Tags:

EQT Foundation announces Rare Disease Science Grant recipients

eqt

EQT Foundation is proud to announce the recipients of its Rare Disease Science Grants, a funding initiative designed to accelerate transformative deeptech solutions for the diagnosis, treatment, and management of rare conditions. The selected projects span gene and RNA therapies, regenerative medicine, AI-enabled diagnostics, novel drug delivery platforms, and precision immunotherapy, each addressing urgent unmet needs in diseases that disproportionately affect children and underserved patient populations.

Together, these projects exemplify the power of rare disease research to generate breakthroughs with impact far beyond individual conditions, advancing new platforms, tools, and approaches that can reshape medicine more broadly.

Meet the Grantees

Spencer Shelton – Modulating metabolic flux by hematopoietic stem cell engineering to ameliorate porphyrias

A broadly applicable genetic therapy for erythropoietic protoporphyria that targets blood stem cells to restore balance in heme biosynthesis. By intervening at a shared regulatory point rather than correcting individual mutations, this approach aims to deliver a mutation-agnostic therapy capable of reaching clinical testing by the end of the project.

Daniel Bauer – Prime editing gene therapy for Shwachman-Diamond syndrome

This project advances a first-in-class prime editing strategy to treat Shwachman-Diamond syndrome, a rare inherited bone marrow failure disorder with no targeted therapies. Building on strong proof-of-concept data, the team will generate the preclinical and genotoxicity evidence needed to support a pre-IND meeting with the FDA, with the longer-term goal of establishing a gene-editing platform for blood and immune diseases.

Rhian Stavely – Autologous enteric neural stem cells for Hirschsprung disease

A curative regenerative medicine approach for children with Hirschsprung disease, which is caused by the absence of enteric neurons in the gut. Using a patient’s own cells, this project aims to regenerate functional enteric neural networks, restore gut motility, and reduce lifelong complications, while preparing the therapy for first-in-human clinical translation.

Marta M. Alonso and Iker Ausejo-Mauleón –Developing new generation oncolytic virus for pediatric brain tumors

This project is developing next-generation oncolytic virus therapies for otherwise incurable pediatric brain tumors, with a focus on diffuse midline gliomas. The grant will support advanced preclinical validation of POP-02, alongside regulatory planning toward first-in-human studies in Europe and the United States, with the ambition to initiate a Phase I trial in children.

Guei-Sheung Liu – Transformative RNA editing therapy for Usher syndrome

This project from the Centre for Eye Research Australia, is developing a first-in-class RNA editing therapy to directly correct the genetic cause of Usher syndrome, a condition that leads to irreversible vision loss and early-onset hearing impairment. By restoring essential retinal proteins, the approach has the potential to halt retinal degeneration and transform outcomes for up to 300,000 people worldwide.

Timothy Jenkins – AI-designed T-cell engagers for virus-driven Merkel cell carcinoma

Using de novo protein design, this project creates highly selective bispecific T-cell engagers that target viral peptide–MHC complexes in Merkel cell carcinoma, a rare and aggressive skin cancer. The platform combines generative AI with in vitro and in vivo validation to deliver a preclinical lead with a clear path toward IND-enabling studies and broader applicability to other virus-associated cancers.

Wouter van Rheenen and Vamshidhar R. Vangoor – ATTAIN: Antisense therapies targeting ALS in induced neurons

ATTAIN aims to rapidly translate genetic discoveries into gene-targeted therapies for ALS. By building a scalable pipeline using patient-derived motor neurons, the team will screen and optimize allele-specific antisense oligonucleotides, nominating lead candidates for safety testing and future first-in-human precision therapies.

Stefan Marciniak – AI-enabled diagnosis of Birt-Hogg-Dubé syndrome

This project applies federated learning and artificial intelligence to improve CT-based diagnosis of Birt-Hogg-Dubé syndrome using multi-institutional data without sharing patient information. By combining imaging, radiomics, and molecular data, the approach aims to improve diagnostic accuracy in non-specialist settings and establish a scalable, privacy-preserving framework for rare disease diagnostics.

Feyisayo Eweje – ENTER: Elastin-based nanoparticles for therapeutic delivery

This project is developing a non-viral protein nanoparticle system for targeted in vivo delivery of gene editors to hematopoietic stem cells. By overcoming key limitations of ex vivo gene editing, this platform aims to enable scalable genetic medicines for inherited blood and immune disorders such as sickle cell disease and beta-thalassemia.

Ana Topf – Latin-SEQ

Latin-SEQ is a multi-centre consortium focused on rare neuromuscular diseases in Latin America. The project integrates diagnosis, gene discovery, and translational development while building sustainable, locally owned scientific infrastructure. By enabling federated analyses and cross-site learning, Latin-SEQ promotes equitable collaboration and long-term capacity building in the region.

Annelisa Cornel – MetaboCAR

MetaboCAR is developing next-generation CAR-T therapies that exploit shared metabolic vulnerabilities across childhood cancers. By targeting metabolic stress signals rather than tumor-specific antigens, this approach aims to unlock new, broadly applicable immunotherapies for pediatric oncology.

Kim Fabiano Marquart – Nerai Bioscience

Nerai Bioscience combines AI with high-throughput directed evolution to engineer customized CRISPR gene-editing tools capable of targeting disease mutations currently beyond reach. With applications in rare genetic liver and metabolic diseases such as citrullinemia type I and phenylketonuria, the project seeks to expand access to first-in-class genome medicines.

Contact

EQT Press Office

press@eqtpartners.com

About EQT

EQT is a purpose-driven global investment organization focused on active ownership strategies. With a Nordic heritage and a global mindset, EQT has a track record of more than three decades of developing companies across multiple geographies, sectors and strategies. EQT has investment strategies covering all phases of a business’ development, from start-up to maturity. EQT has €‌​​270​‌ billion in total assets under management (€141​‌ billion in fee-generating assets under management) as of 31 December 2025, within two business segments – Private Capital and Real Assets.

With its roots in the Wallenberg family’s entrepreneurial mindset and philosophy of long-term ownership, EQT is guided by a set of strong values and a distinct corporate culture. EQT manages and advises funds and vehicles that invest across the world with the mission to future-proof companies, generate attractive returns and make a positive impact with everything EQT does.

The EQT AB Group comprises EQT AB (publ) and its direct and indirect subsidiaries, which include general partners and fund managers of EQT funds as well as entities advising EQT funds. EQT has offices in more than 25 countries across Europe, Asia and the Americas and has more than 1,900 employees.

More info: www.eqtgroup.com
Follow EQT on LinkedIn, X, YouTube and Instagram

Categories: News

Tags: